BI 655130

Drug Profile

BI 655130

Alternative Names: BI655130

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antipsoriatics; Antiulcers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Palmoplantar pustulosis; Ulcerative colitis
  • Phase I Pustular psoriasis

Most Recent Events

  • 07 Jun 2017 Phase-II clinical trials in Ulcerative colitis (Adjunctive treatment) in Norway, Spain (unspecified route) (NCT03123120) (EudraCT2016-004572-21)
  • 06 Jun 2017 Phase-I clinical trials in Pustular psoriasis (In volunteers) in South Korea (SC) (NCT03123094)
  • 30 May 2017 Phase-II clinical trials in Palmoplantar pustulosis in Spain (IV) (NCT03135548)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top